Big Pharma Doubles Down on CRISPR for New Drugs A joint venture between Bayer and CRISPR Therapeutics is the latest effort to make CRISPR drugs that could target and modify cells inside the body.
In Pursuit of an Affordable Tablet for the Blind By borrowing from microfluidics, a team of University of Michigan researchers are reinventing the Braille display to be cheaper and more useful.